Sublocade (buprenorphine) and Vivitrol (naltrexone) are prescription drugs used to treat opioid use disorder. Vivitrol is also prescribed for alcohol use disorder. Both drugs come as an injection ...

If you’re considering treatment for opioid use disorder (OUD), your doctor may recommend Sublocade. It’s prescribed as part of a complete treatment program to manage opioid addiction in adults with ...

Sublocade (buprenorphine) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat moderate to severe opioid use disorder in people who received ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

Sublocade (buprenorphine) is a brand-name extended-release injection that’s prescribed for opioid use disorder. Sublocade has interactions with alcohol, some other drugs, and certain supplements.

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

RICHMOND, Va. - Indivior PLC (NASDAQ:LSE: INDV), a pharmaceutical company, has shared research findings emphasizing the efficacy and safety of its medication, SUBLOCADE, for individuals recovering ...

Alberta to provide new opioid treatment for free As opioid-related 911 calls spike in the province, a new opioid treatment is being offered free of charge to help people survive drug addiction.

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...

Indivior recently released results from a multicenter, open-label clinical trial showing that rapid induction with SUBLOCADE, using a single 4 mg oral buprenorphine dose followed by a same-day ...